Type 2 Diabetes Trial, Recruiting NCT07716059 Sponsor: Harokopio University Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07716059
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

Healthy Adults Group:

  • Adults between 18 and 35 years old
  • People who are generally healthy with no diagnosed long-term conditions, such as diabetes, heart disease, or digestive disorders
  • People whose Body Mass Index (BMI) falls between 18.5 and 27 (a measure of body weight relative to height)
  • People whose fasting blood sugar level is in the normal range (below 100 mg/dL or 5.6 mmol/L)
  • People who do not regularly take medications that affect how the body processes sugar (such as insulin, metformin, or steroids)
  • People who are willing and able to follow study procedures, including wearing a continuous glucose monitor and eating specific test meals provided by the study
  • People who are able to understand and sign a written consent form

Type 2 Diabetes Group:

  • Men and women between 40 and 75 years old
  • People with a BMI below 31
  • People whose fasting blood sugar level is above 125 mg/dL
  • People whose HbA1c (a measure of average blood sugar over several months) is below 8.5%
  • People who have had a confirmed diagnosis of type 2 diabetes for at least one year before joining the study
  • People who have been on stable medication for blood sugar, cholesterol, and/or blood pressure management for at least three months before joining

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

Healthy Adults Group:

  • People who have been diagnosed with type 1 or type 2 diabetes, heart disease, kidney or liver disease, or digestive conditions such as celiac disease or inflammatory bowel disease
  • People whose fasting blood sugar or HbA1c levels fall outside the normal range specified above
  • People who regularly take medications that affect blood sugar, insulin sensitivity, or digestion (such as metformin, steroids, or GLP-1 medications)
  • People who have an allergy or intolerance to wheat, chickpeas, gluten, or other ingredients used in the study foods
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
  • People who have had a significant change in body weight (more than 5% of total body weight) in the past three months
  • Competitive athletes or people following extreme exercise routines, as these could affect blood sugar results
  • People who are unable or unwilling to follow the study procedures, including glucose monitoring and eating the set study meals

Type 2 Diabetes Group:

  • People who have hormone-related, heart, lung, kidney, or digestive conditions that could affect the study results
  • People who have a sensitivity, intolerance, or allergy to any ingredients in the study breads
  • Women who are pregnant or breastfeeding
  • People who have a diagnosed eating disorder
  • People taking medications or dietary supplements that the study team considers incompatible with the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +306937900141

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Harokopio University
Registry
ClinicalTrials.gov
Start date
29 September 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Postprandial incremental blood glucose area under the curve (iAUC₀-₁₈₀ min), measured by continuous glucose monitoring, after consumption of the bread enriched with 30% larger particle size compared with white wheat bread.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov